Table 3.
Drug efficacy in PDX models and OncoVee® MiniPDX capsules in mice
| Model | Location | Pathology | Chemotherapeutic or targeted drug (Regimen) | TGI (%) | Response in PDX | TCGI(%) | Response in MiniPDX |
|---|---|---|---|---|---|---|---|
| GAYW5 | Stomach | Poor/moderately differentiated AC, 80% | S-1 (1) | 95 ± 6 | + | 94 ± 15 | + |
| GAYW7 | Stomach | Poorly differentiated AC, 90% | S-1 (1) | 86 ± 10 | + | 92 ± 3 | + |
| GAYL1 | Stomach | Mucinous AC, 80% | S-1 (1) | 37 ± 10 | – | 13 ± 29 | – |
| GAYB7 | Stomach | Poorly differentiated tubular AC, 70% | S-1 (1) | 44 ± 16 | – | 14 ± 20 | – |
| GAYP53 | Stomach | Poor-moderately differentiated AC, 90% | S-1 (1) | 35 ± 10 | – | 17 ± 13 | – |
| GASIL2 | Stomach | Moderately differentiated AC, 40% | S-1 + Oxaliplatin (2) | 29 ± 20 | – | 40 ± 17 | – |
| GABSI3 | Stomach | Poorly differentiated AC, 80% | S-1 + Oxaliplatin (2) | 37 ± 12 | – | 75 ± 4 | + |
| GAYP93 | Stomach | Moderately differentiated AC, 90% | S-1 + Oxaliplatin(2) | 27 ± 20 | – | 29 ± 15 | – |
| GAYP97 | Stomach | Moderately differentiated AC, 90% | S-1 + Oxaliplatin (2) | 7 ± 29 | – | 9 ± 10 | – |
| GAJ07 | Stomach | Poor-moderately differentiated AC, 50% | Capecitabine + Oxaliplatin (3) | 80 ± 3 | + | 35 ± 13 | – |
| GASI80 | Stomach | Poorly differentiated AC, 80% | Capecitabine + Oxaliplatin (3) | 112 ± 3 | + | 50 ± 11 | + |
| GASI05 | Stomach | Moderately differentiated AC, 40% | Epirubicin + Capecitabine + Oxaliplatin (4) | 97 ± 16 | + | 45 ± 23 | + |
| GASAB3 | Stomach | Poorly differentiated AC, 90% | Cisplatin + 5-FU + Docetaxel (5) | 43 ± 17 | – | 17 ± 14 | – |
| GAYP16 | Stomach | Poorly differentiated AC, 90% | Cisplatin + 5-FU + Docetaxel (5) | 32 ± 16 | – | −13 ± 39 | – |
| GAYP53 | Stomach | Poor-moderately differentiated AC, 90% | Cisplatin + 5-FU + Docetaxel (5) | 125 ± 3 | + | 50 ± 7 | + |
| LULI02 | Lung | Poorly differentiated SCC, 98% | Docetaxel (6) | 97 ± 12 | + | 51 ± 7 | + |
| LULI03 | Lung | Poorly differentiated AC, 98% | Docetaxel (6) | 12 ± 23 | – | 15 ± 10 | – |
| LULI20 | Lung | Poorly differentiated AC, 98% | Docetaxel (6) | 91 ± 14 | + | 86 ± 3 | + |
| LULI21 | Lung | Poorly differentiated SCC, 78% | Docetaxel (6) | 42 ± 16 | – | −61 ± 29 | – |
| LULI27 | Lung | Moderate-highly differentiated SCC, 80% | Docetaxel (6) | 115 ± 3 | + | 32 ± 11 | – |
| LULI55 | Lung | Large cell carcinoma, 95% | Docetaxel (6) | 109 ± 1 | + | 14 ± 4 | – |
| CTYW012 | Lung | Poor-moderately differentiated AC, 90% | Gemzar + Cisplatin (7) | 116 ± 0 | + | 84 ± 7 | + |
| LULI49 | Lung | Poorly differentiated AC, 90% | Erlotinib (8) | 40 ± 15 | – | −16 ± 26 | – |
| CTC15063 | Lung | Poor-moderately differentiated AC, 95% | Erlotinib (8) | 37 ± 19 | – | 21 ± 17 | – |
| CTC15063 | Lung | Poor-moderately differentiated AC, 95% | AZD9291 (9) | 167 ± 5 | + | 61 ± 3 | + |
| CTC16075 | Lung | Poorly differentiated carcinoma, 90% | Crizotinib (10) | 103 ± 2 | + | 102 ± 4 | + |
| PAYY8 | Pancreas | Poorly differentiated ductal AC, 90% | Gemzar (11) | 27 ± 27 | – | −14 ± 10 | – |
| PAYY5 | Pancreas | Poor-moderately differentiated ductal AC, 80% | Gemzar (11) | 75 ± 9 | + | 56 ± 8 | + |
| PAYY5 | Pancreas | Poor-moderately differentiated ductal AC, 80% | Oxaliplatin + Irinotecan (12) | 112 ± 2 | + | 54 ± 6 | + |
Model: Indicates a specific patient and patient-derived xenograft model
Pathology: Judged by licensed pathologist (SY); %, percentage of the diseased cells judged by pathology; AC adenocarcinoma, SCC squamous cell carcinoma
Regimen: Drug combinations used to test efficacy in specific PDX model and MiniPDX
Chemotherapeutic or targeted drug: Single or combination of drugs used in PDX assay and in MiniPDX
TGI: Tumor growth inhibition or TCGI: tumor cell growth inhibition. N = 6, results are mean ± SEM. Mean TGI or TCGI ≥ 45% is defined as positive therapeutic response (+)